Brain Tumor Protocols / Clinical Studies

For more information on any of the protocols listed below, please contact:

Amar Gajjar, MD
Director of Neuro-Oncology

or

Tabatha Doyle, RN
Coordinator, Brain Tumor Program

(901) 595-2544

Contact us anytime, 24 hours a day, 7 days a week.

 

Phase I Study of the Combination of Vandetanib and Dasatinib Administered During and After Radiation Therapy in Children with Diffuse Intrinsic Pontine Glioma

For: Diffuse intrinsic pontine glioma

 
 

A Phase I/II Trial of a New Tyrosine Kinase Inhibitor (Tarceva; Erlotinib Hydrochloride; OSI-774) during and after Radiotherapy in the Treatment of Patients with Newly Diagnosed High-Grade Glioma and Unfavorable Low-Grade Glioma

For: Intracranial high-grade glioma and unfavorable low-grade glioma

 
 

Treatment of Patients with Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor (PNET), or Atypical Teratoid Rhabdoid Tumor (ATRT)

For: Medulloblastoma, supratentorial primitive neuroectodermal tumor (PNET), atypical teratoid rhabdoid tumor (ATRT), ependymoblastoma, pineoblastoma, central nervous system (CNS) neuroblastoma

 
 

Risk-Adapted Therapy for Children Less Than 3 Years of Age with Embryonal Brain Tumors, High-Grade Glioma, Choroid Plexus Carcinoma or Ependymoma

For: Embryonal brain tumors, choroid plexus carcinoma or ependymoma

 

Non St. Jude Protocols

 

A Phase II Study of Conformal Radiotherapy in Patients with Low-Grade Gliomas (ACNS0221)

For: Central Nervous System Tumors

 
 

Phase III Radiotherapy Alone vs. Chemotherapy Followed by Response-based Radiotherapy for Newly Diagnosed Primary CNS Germinoma (ACNS0232)

For: Germinoma

 
 

Cilengitide (EMD 121974) (IND# 59073) in Recurrent or Progressive and Refractory Childhood High-Grade Glioma

For: Gliomas

 
 

A Phase I Pharmacokinetic Optimal Dosing Study of Intraventricular Topotecan for Children with Neoplastic Meningitis

For: Neoplastic meningitis

 
 

A Phase I Clinical Trial of AZD2171 In Children With Recurrent or Progressive Central Nervous Systems (CNS) Tumors

For: Recurrent or Progressive Central Nervous System (CNS) Tumors

 
 

Phase II study of Bevacizumab plus Irinotecan (Camptosar) in Children with Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas

For: Gliomas

 
 

Phase I and Pharmacokinetic Study of Enzastaurin (LV317615) in Children and Adolescents with Refractory Primary CNS Tumors

For: Brain tumors

 
 

A Phase 1 study of MK-0752 in Pediatric Patients with Recurrent or Refractory CNS Malignancies

For: Brain tumors

 
 

A Phase I Pharmacokinetic and Safety Study in Children with Recurrent or Refractory Medulloblastoma to Identify a Pharmacokinetic Based Dose for GDC-0449

For: Brain tumors

 
Email This Article Email This Article   |   Print Print